The present invention provide a method for assessing the sensitivity to a pyrimidine drug such as 5-FU which is degraded in the pyrimidine metabolic pathway, specifically in vivo pyrimidine metabolizing activity, of an individual subject; and a preparation useful for the assessment. The present invention can be carried out by: administering a preparation comprising as an active ingredient a pyrimidine compound or its metabolite which acts as a substrate for a pyrimidine metabolizing enzyme, in which compound or metabolite at least one of C, O and N is labeled with an isotope; and assessing in vivo pyrimidine metabolizing activity based on the amount of excreted metabolite.
Yasuo Irie - Reading MA, US Anil S. Modak - Methuen MA, US
Assignee:
Cambridge Isotope Laboratories - Andover MA
International Classification:
A61B005/00
US Classification:
600532, 73 233, 422 84
Abstract:
The present invention relates to an assay for evaluating alveolar exchange of oxygen. A C-labeled substrate, such as C-sodium bicarbonate is administered to a subject by oral or iv intake, and exhaled COis measured. The COin expired breath can be collected at various time points following administration of the substrate and measured in Δ per mil with a mass analyzer or photometer, such as an IR spectrometer. This process can be used as a diagnostic test for the indication of, treatment and/or evaluation of the severity of respiratory tract diseases or infections.
Preparation For Determining Pyrimidine Metabolic Capacity
The present invention provide a method for measuring and assessing the capacity in an individual subject to metabolize a variety of fluorouracil drugs, such as 5-fluorouracil, which are degraded in the pyrimidine metabolic pathway, and a preparation useful for the measurement and assessment. The present invention can be carried out by: administering a preparation for determining pyrimidine metabolic capacity comprising as an active ingredient a pyrimidine compound or pyrimidine metabolic compound that acts as a substrate for a pyrimidine metabolizing enzyme, in which at least one of the carbon, oxygen, and nitrogen atoms is labeled with an isotope; and assessing in vivo pyrimidine metabolic capacity based on the behavior of an excreted metabolite.
Composition For Determining Pyrimidine Metabolizing Activity
The present invention provide a method for assessing the sensitivity to a pyrimidine drug such as 5-FU which is degraded in the pyrimidine metabolic pathway, specifically in vivo pyrimidine metabolizing activity, of an individual subject; and a preparation useful for the assessment. The present invention can be carried out by: administering a preparation comprising as an active ingredient a pyrimidine compound or its metabolite which acts as a substrate for a pyrimidine metabolizing enzyme, in which compound or metabolite at least one of C, O and N is labeled with an isotope; and assessing in vivo pyrimidine metabolizing activity based on the amount of excreted metabolite.
Method For Monitoring Patient Or Subject Compliance With Medical Prescriptions, And Formulation For Use In The Method
Yasuo Irie - Woburn MA, US Anil Modak - Methuen MA, US Tadashi Mukai - Naruto-shi, JP
International Classification:
A61K 49/00
US Classification:
424009100
Abstract:
The present invention provides a highly accurate method for monitoring patient or subject compliance with a medication prescription by collecting a sample of the exhaled air. The method of the present invention is easy and little burdens the patient or subject. The method comprises the steps of: (i) prescribing a patient or subject ingestion of at least one biologically active agent and at least one carbon isotope-labeled lipid, (ii) obtaining a sample of the patient's or subject's exhaled air, (iii) measuring the ratio of the carbon isotope-labeled COrelative to COin the sample; and (iv) confirming the ingestion of the prescribed biologically active agent based on the ratio of the carbon isotope-labeled COrelative to CO.
Method And Composition To Evaluate Cytochrome P450 2D6 Isoenzyme Activity Using A Breath Test
Anil Modak - Methuen MA, US Yasuo Irie - Reading MA, US Yasuhisa Kurogi - North Andover MA, US
International Classification:
C12Q 1/26
US Classification:
435025000
Abstract:
The present invention relates, generally to a method of determining and assessing cytochrome P450 2D6 isoenzyme (CYP2D6)-related metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of COexhaled by a the subject upon intravenous or oral administration of a C-labeled CYP2D6 substrate compound. The present invention is useful as an in vivo phenotype assay for evaluating CYP2D6-related activity using the metabolite COin expired breath and to determine the optimal dosage and timing of administration of CYP2D6 substrate compound.
Name / Title
Company / Classification
Phones & Addresses
Yasuo Irie Director
GALENEA CORP Industrial Building Construction · Research & Development in Biotechnology
50C Audubon Rd, Wakefield, MA 01880 300 Technology Sq, Cambridge, MA 02139 50 Audubon Rd, Wakefield, MA 01880 (617)3741010